These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3032200)

  • 1. Pitfalls in demonstrating an endogenous ligand of imipramine recognition sites.
    Lee CR; Galzin AM; Taranger MA; Langer SZ
    Biochem Pharmacol; 1987 Mar; 36(6):945-9. PubMed ID: 3032200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of [3H]paroxetine binding in rat brain.
    Marcusson JO; Bergström M; Eriksson K; Ross SB
    J Neurochem; 1988 Jun; 50(6):1783-90. PubMed ID: 2967349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for the existence of serotonin uptake inhibitor-like substances in human cerebrospinal fluid.
    Goto S; Egashira T; Yamanaka Y
    Jpn J Pharmacol; 1991 Jul; 56(3):297-302. PubMed ID: 1832727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High affinity binding of 3H-paroxetine and 3H-imipramine to rat neuronal membranes.
    Mellerup ET; Plenge P
    Psychopharmacology (Berl); 1986; 89(4):436-9. PubMed ID: 2944152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional distribution of the serotonin transport complex in human brain, identified with 3H-paroxetine, 3H-citalopram and 3H-imipramine.
    Plenge P; Mellerup ET; Laursen H
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):61-72. PubMed ID: 2137251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant binding sites in brain: autoradiographic comparison of [3H]paroxetine and [3H]imipramine localization and relationship to serotonin transporter.
    Hrdina PD; Foy B; Hepner A; Summers RJ
    J Pharmacol Exp Ther; 1990 Jan; 252(1):410-8. PubMed ID: 2137177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of [3H]-imipramine and [3H]-paroxetine binding with the 5HT transporter in brain and platelets: relevance to studies in depression.
    Langer SZ; Galzin AM; Poirier MF; Loo H; Sechter D; Zarifian E
    J Recept Res; 1987; 7(1-4):499-521. PubMed ID: 3040983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A common binding site for tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors at the substrate recognition site of the neuronal sodium-dependent 5-hydroxytryptamine transporter.
    Graham D; Esnaud H; Habert E; Langer SZ
    Biochem Pharmacol; 1989 Nov; 38(21):3819-26. PubMed ID: 2532013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of MAO activity, 3H-imipramine binding, 3H-paroxetine binding and 3H-5-HT uptake by human cerebrospinal fluid.
    Egashira T; Goto S; Murayama F; Yamanaka Y
    J Neural Transm Suppl; 1990; 32():447-56. PubMed ID: 2150970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affinity modulation of [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and platelets.
    Plenge P; Mellerup ET; Laursen H
    Eur J Pharmacol; 1991 Mar; 206(3):243-50. PubMed ID: 1830276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the serotonin transporter in platelets.
    Langer SZ; Galzin AM
    Experientia; 1988 Feb; 44(2):127-30. PubMed ID: 2964377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociation kinetics of [3H]paroxetine binding to rat brain consistent with a single-site model of the antidepressant binding/5-hydroxytryptamine uptake site.
    Marcusson J; Eriksson K
    J Neurochem; 1988 Nov; 51(5):1477-81. PubMed ID: 2971784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-specific inhibition of imipramine binding argues against an endogenous ligand.
    Artigas F; Martínez E; Adell A
    Eur J Pharmacol; 1990 May; 181(1-2):9-15. PubMed ID: 2387322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet 3H-paroxetine binding to the serotonin transporter is insensitive to changes in central serotonergic innervation in the rat.
    Moret C; Briley M
    Psychiatry Res; 1991 Aug; 38(2):97-104. PubMed ID: 1836639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressive drugs can change the affinity of [3H]imipramine and [3H]paroxetine binding to platelet and neuronal membranes.
    Plenge P; Mellerup ET
    Eur J Pharmacol; 1985 Dec; 119(1-2):1-8. PubMed ID: 2935414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Isolation of substances inhibiting the specific binding of imipramine and serotonin uptake from the brain of the bull].
    Mukhin AG; Kladnitskiĭ AV; Kovaleva ES; Kudriakova TB
    Biull Eksp Biol Med; 1985 Aug; 100(8):197-9. PubMed ID: 2992631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [3H]paroxetine binding and serotonin content of rat and rabbit cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region.
    Dewar KM; Reader TA; Grondin L; Descarries L
    Synapse; 1991 Sep; 9(1):14-26. PubMed ID: 1724575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of [3H]paroxetine binding to the 5-hydroxytryptamine uptake site in an animal model of depression.
    Edwards E; Harkins K; Wright G; Henn F
    J Neurochem; 1991 May; 56(5):1581-6. PubMed ID: 1826517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of [3H]paroxetine and [3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain.
    Gurevich EV; Joyce JN
    Neuropsychopharmacology; 1996 May; 14(5):309-23. PubMed ID: 8703300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen.
    Raisman R; Cash R; Agid Y
    Neurology; 1986 Apr; 36(4):556-60. PubMed ID: 2938025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.